So just when will the FDA approve this hopefully helpful men’s testosterone booster? To answer that, we have to realize that Androxal has already pass many key FDA milestones:
1. Successfully completion of all phase III trials.
2. The submittal of an NDA (New Drug Application) in Feb. of 2014.
At this point Repros Pharmaceuticals is just waiting to hear from the FDA if the drug will be approved or not. The new should be favorable in my opinion, because a) Androxal did well in Phase III trials and b) the stock price has held up quite well since the NDA: the stock peaked at about $9.85 in February, then fell a little and came back to $8.53 as of this writing in August of 2015. So investors and instititions still clearly believe the Androxal situation looks favorable.
At this point, it is strictly a matter of timing. For awhile drugs were generally approved in 0.6 to 2.0 years from the time of the NDA application.  However, the environment has completely changed with the Prescription Drug User Fee Act which now requires that the lion’s share of FDA NDA be approved within 10 months. Here are the arguments for short and long scenarios:
i) Longer. I think it is reasonable to assume that it will be on the longer side rather than shorter, i.e. in the 8-10 month range. And the reason is simply that there has been a good deal of controversy of late centering around testosterone-related products. Last year, there was a a wave of litigation that arose against the big pharmaceutical testosterone manufacturers, something I cover in the page called Testosterone Pharmaceutical Class Action Lawsuits after a couple of studies that showed increased cardiovascular risk for men on HRT.
ii) Shorter. Recently Aveed (Nebido) did an NDA application in September of 2013 and was approved by the FDA in March. This shorter six month approval time was suprising considering the reports of a couple of anaphalytic shock victims and the procedures necessary to comfort the FDA, etc. One cold argue that Androxal’s approval should actually be easier than Aveed.
CONCLUSION: The optimistic time for FDA approval is September of 2015 and the pessimistic December of 2015.
NEWS FLASH: Investopedia is reporting the following: “The company anticipates an FDA approval decision by November 30, 2015 for Androxal, a potential treatment for secondary hypogonadism. The FDA is also planning to hold an advisory committee (ADCOM) meeting to discuss the approvability of Androxal, on November 3, 2015. If the ADCOM recommends Androxal for approval, it will significantly impact share price.” 
NOTE: A potential issue with Androxal is that it may not provide much of a T boost. See my page on Testosterone and Androxal for more information.